This preliminary population is of interest because higher KL-6 concentrations were recorded in IPF-LC patients than in the IPF and fHP groups, demonstrating that KL-6 may be a useful prognostic biomarker, predictive of IPF progression. The gene discussed is MUC1; the disease is laryngotracheoesophageal cleft.